Showing results (41-50 of 47) with videos related to
Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2010
Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapyXin Dong, Jun Guan, John C English, et al.Investigational New Drugs|January 29, 2013
A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortiumSrikala S Sridhar, Mary J Mackenzie, Sebastien J Hotte, et al.Oncotarget|October 21, 2017
A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196Natasha B Leighl, Ming-Sound Tsao, Geoffrey Liu, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 19, 2011
Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials GroupScott A Laurie, Ashish Gupta, Quincy Chu, et al.Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada|January 2, 2015
Evaluation of second-line and subsequent targeted therapies in metastatic renal cell cancer (mRCC) patients treated with first-line cediranibSuzanne Richter, Jo-An Seah, Gregory R Pond, et al.Plos One|May 26, 2012
Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor developmentWilliam W Lockwood, Ian M Wilson, Bradley P Coe, et al.Lung Cancer (Amsterdam, Netherlands)|June 16, 2019
Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219Barbara Melosky, Penelope Bradbury, Dongsheng Tu, et al.Pageof 5